AlphaYou
Overview
Smart money at a glance
Filings to Oct 7, 2026Net selling: insiders sold $45K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$45K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, latest quarter
- NoneNo large changes
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 6- Open
- $21.02
- 52-wk high
- $37.50
- High
- $21.74
- 52-wk low
- $18.19
- Low
- $20.50
- Prev close
- $20.60
- Mkt cap
- $78.5M
- Volume
- 69.6K
- Beta
- 3.11
- P/S
- 1.8x
- P/B
- 2.9x
- Profit margin
- -199.5%
- Op margin
- -101.4%
- ROE
- -333.8%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about PTHS filings
Are insiders buying or selling Pelthos Therapeutics Inc. (PTHS) stock?
Net selling: insiders sold $45K and bought $0 of PTHS stock on the open market in the 90 days to Oct 7, 2026, according to SEC Form 4 filings. $45K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Greenleaf, Peter (Director), who sold $17K. The latest filing was on Oct 6, 2026.
Which members of Congress have traded PTHS recently?
None. No member of Congress disclosed a PTHS trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this PTHS smart-money data?
This summary uses filings available on Oct 7, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
3 funds hold a position and insiders have been net selling.
What insiders are doing
How top traders are positioned
No tracked top-trader positions in PTHS right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 30.2% below what analysts expected.
Last report
May 14, 2026
Period ending
Mar 31, 2026
Earnings per share
-$3.58 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Mar 31, 2026 | May 14, 2026 | -$4.66 / -$3.58Alpha Vantage | -30.24% miss | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 19, 2026 | -$2.69 / -$4.18Alpha Vantage | +35.65% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 13, 2025 | -$5.30 / -$0.57Alpha Vantage | -$4.73 miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 13, 2025 | -$5.38 / -$6.26Alpha Vantage | +14.06% beat | Unavailable | Unavailable |
| Mar 31, 2025 | May 28, 2025 | Unavailable | - | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 26, 2025 | Unavailable | - | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 13, 2024 | -$2.90 / -$2.30Alpha Vantage | -26.09% miss | Unavailable | Unavailable |
| Jun 30, 2024 | Aug 13, 2024 | -$3.10 / -$2.90Alpha Vantage | -6.90% miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 12, 2026, in 36 days
Financials
Is the business strong?
This company is not yet profitable.
- Net margin
- -199.5%
- Market cap
- $78M
Valuation
- P/S1.81
- P/B2.86
Quality
- Operating margin-101.4%
- ROE-333.8%
- ROA-50.0%
Growth
- Beta3.11
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
15 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace